The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study
Open accessAbstract
Background Monoclonal gammopathy of undetermined significance (MGUS) is a common premalignant plasma cell disorder defined by evidence of immunoglobulin heavy chain (IgH expression). MGUS is the precursor lesion for most cases of multiple myeloma (MM), but up to 20% of MM is characterized by complete lack of IgH expression; the prevalence of a corresponding precursor entity, light chain MGUS (LC-MGUS) is unknown. Methods We studied 18,357 Olmsted County, Minnesota, residents age 50 years or older with the serum free light chain (FLC) assay. LC-MGUS was defined as an abnormal FLC-R with complete lack of IgH expression, plus elevation in the appropriate involved FLC. Findings An abnormal FLC-R was observed in 3.3% persons tested. Of these, 213 had IgH expression on immunofixation diagnostic of conventional MGUS, 57 of whom were previously undetected. Among the remaining 397 individuals, 146 had elevation of at least one FLC and met criteria for LC-MGUS. The prevalence of LC-MGUS was 0.8%, bringing the overall prevalence of MGUS+LC-MGUS to 4.2% among persons age 50-years and older. The risk of progression to MM among the LC-MGUS patients was 0.3% (95% confidence interval [CI], 0.1 to 0.8%)/year. Twenty-three percent of LC-MGUS patients had renal disease either at the time of or subsequent to acquisition of the test sample. Interpretation LC-MGUS is prevalent in approximately 1% of a predominantly Caucasian, general population and poses a risk of progression to light-chain MM and related conditions comparable to that of low-risk MGUS. LC-MGUS was also associated with a risk for renal disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Modeling Survival Data: Extending the Cox Model
Therneau, T. M., & Grambsch, P. M. (2000) · Statistics for Biology and Health · doi:10.1007/978-1-4757-3294-8 · Cited by 8,674
Self-citationBrown, R. A., Hastie, T. J., & Tibshirani, R. J. (1991) · Biometrics · doi:10.2307/2532174 · Cited by 8,176
Koyak, R. A., Hastie, T. J., & Tibshirani, R. J. (1991) · Journal of the American Statistical Association · doi:10.2307/2290538 · Cited by 7,596
Hastie, T., & Tibshirani, R. (2014) · Wiley StatsRef: Statistics Reference Online · doi:10.1002/9781118445112.stat03141 · Cited by 3,156
International Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974
Self-citationReview of 1027 Patients With Newly Diagnosed Multiple Myeloma
Kyle, R. A., Gertz, M. A., Witzig, T. E., Lust, J. A., Lacy, M. Q., Dispenzieri, A., Fonseca, R., Rajkumar, S. V., Offord, J. R., Larson, D. R., et al. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.1.21 · Cited by 2,447
Self-citationThe International Myeloma Working Group (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04355.x · Cited by 2,321
A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa01133202 · Cited by 1,475
Self-citationPrevalence of monoclonal gammopathy of undetermined significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Larson, D. R., Plevak, M. F., Offord, J. R., Dispenzieri, A., Katzmann, J. A., & Melton, L. J. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054494 · Cited by 1,423
Self-citationLandgren, O., Kyle, R. A., Pfeiffer, R. M., Katzmann, J. A., Caporaso, N. E., Hayes, R. B., Dispenzieri, A., Kumar, S., Clark, R. J., Baris, D., et al. (2009) · Blood · doi:10.1182/blood-2008-12-194241 · Cited by 1,127
Self-citation
Research works printed but not linked: 3
- Mead, 2003, Detection of Bence Jones myeloma and monitoring of myeloma chemotherapy using immunoassays specific for free immunoglobulin light chains, Clin Lab, 49, 25
- Kyle, 1982, “Idiopathic” Bence Jones proteinuria: long-term follow-up in seven patients, N Engl J Med, 306, 564, 10.1056/NEJM198203113061002 · doi:10.1056/nejm198203113061002
- Magrangeas, 2004, Light-chain only multiple myeloma is due to the absence of functional (productive) rearrangement of the IgH gene at the DNA level, Blood, 103, 3869, 10.1182/blood-2003-07-2501 · DOI
Cited by
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
Self-citationMultiple myeloma: 2022 update on diagnosis, risk stratification, and management
Rajkumar, S. V. (2022) · American Journal of Hematology · doi:10.1002/ajh.26590 · Cited by 883
Self-citationMultiple Myeloma: Diagnosis and Treatment
Rajkumar, S. V., & Kumar, S. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.11.007 · Cited by 812
Self-citationMultiple myeloma: 2020 update on diagnosis, risk‐stratification and management
Rajkumar, S. V. (2020) · American Journal of Hematology · doi:10.1002/ajh.25791 · Cited by 789
Self-citationLong-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance
Kyle, R. A., Larson, D. R., Therneau, T. M., Dispenzieri, A., Kumar, S., Cerhan, J. R., & Rajkumar, S. V. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709974 · Cited by 647
Self-citation
Metadata
- Authors
- Dispenzieri, A., Katzmann, J. A., Kyle, R. A., Larson, D. R., Melton, L. J., Colby, C. L., Therneau, T. M., Clark, R., Kumar, S. K., Bradwell, A., Fonseca, R., Jelinek, D., & Rajkumar, S. V.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2010-05
- Volume
- 375
- Issue
- 9727
- Pages
- 1721-1728
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2151638673
- Cited by
- 394
- References
- 32
- FWCI
- 14.55
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. https://app.cochat.ai/papers/10.1016/s0140-6736(10)60482-5
- The paper
- Dispenzieri, A., Katzmann, J. A., Kyle, R. A., Larson, D. R., Melton, L. J., Colby, C. L., Therneau, T. M., Clark, R., Kumar, S. K., Bradwell, A., Fonseca, R., Jelinek, D., & Rajkumar, S. V. (2010). Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. The Lancet. https://doi.org/10.1016/s0140-6736(10)60482-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.